Loading...

Humanigen

OTCPK:HGEN
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HGEN
OTCPK
$126M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Humanigen has significant price volatility in the past 3 months.
HGEN Share Price and Events
7 Day Returns
-2.4%
OTCPK:HGEN
1.4%
US Biotechs
1.5%
US Market
1 Year Returns
71.8%
OTCPK:HGEN
-7.9%
US Biotechs
1%
US Market
HGEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Humanigen (HGEN) -2.4% -0.7% -10.8% 71.8% -76% -93.1%
US Biotechs 1.4% 1% -8.2% -7.9% 11% 7%
US Market 1.5% 1% 1.4% 1% 37.6% 38.1%
1 Year Return vs Industry and Market
  • HGEN outperformed the Biotechs industry which returned -7.9% over the past year.
  • HGEN outperformed the Market in United States of America which returned 1% over the past year.
Price Volatility
HGEN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Humanigen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Humanigen is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Humanigen has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Humanigen. This is due to cash flow or dividend data being unavailable. The share price is $1.142.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Humanigen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Humanigen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:HGEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.09
OTCPK:HGEN Share Price ** OTCPK (2019-06-14) in USD $1.14
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.33x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Humanigen.

OTCPK:HGEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:HGEN Share Price ÷ EPS (both in USD)

= 1.14 ÷ -0.09

-13.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Humanigen is loss making, we can't compare its value to the US Biotechs industry average.
  • Humanigen is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Humanigen's expected growth come at a high price?
Raw Data
OTCPK:HGEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.14x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Humanigen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Humanigen's assets?
Raw Data
OTCPK:HGEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $-0.09
OTCPK:HGEN Share Price * OTCPK (2019-06-14) in USD $1.14
United States of America Biotechs Industry PB Ratio Median Figure of 424 Publicly-Listed Biotechs Companies 3.01x
United States of America Market PB Ratio Median Figure of 5,242 Publicly-Listed Companies 1.8x
OTCPK:HGEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:HGEN Share Price ÷ Book Value per Share (both in USD)

= 1.14 ÷ -0.09

-13.17x

* Primary Listing of Humanigen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Humanigen has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of HGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Humanigen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Humanigen has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Humanigen expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Humanigen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Humanigen expected to grow at an attractive rate?
  • Unable to compare Humanigen's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Humanigen's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Humanigen's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:HGEN Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:HGEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:HGEN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 -5 -9
2018-12-31 -6 -12
2018-09-30 -7 -13
2018-06-30 -10 -18
2018-03-31 -12 -22
2017-12-31 -14 -22
2017-09-30 -15 -24
2017-06-30 -20 -21
2017-03-31 -23 -27
2016-12-31 -21 -27
2016-09-30 -26 -35
2016-06-30 -23 -37

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Humanigen is high growth as no earnings estimate data is available.
  • Unable to determine if Humanigen is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:HGEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Humanigen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HGEN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.09
2018-12-31 -0.13
2018-09-30 -0.18
2018-06-30 -0.38
2018-03-31 -0.92
2017-12-31 -1.47
2017-09-30 -1.60
2017-06-30 -1.42
2017-03-31 -2.20
2016-12-31 -2.78
2016-09-30 -5.01
2016-06-30 -8.61

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Humanigen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of HGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Humanigen's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Humanigen's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Humanigen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Humanigen has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Humanigen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Humanigen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Humanigen does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Humanigen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Humanigen's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Humanigen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Humanigen Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HGEN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 -9.46 7.03 0.37
2018-12-31 -12.00 9.11 0.45
2018-09-30 -13.03 9.67 0.63
2018-06-30 -18.04 9.86 0.65
2018-03-31 -21.53 9.37 1.34
2017-12-31 -21.99 7.87 1.79
2017-09-30 -23.95 7.39 3.53
2017-06-30 -21.28 7.85 4.19
2017-03-31 -27.14 8.82 4.36
2016-12-31 -27.02 7.58 4.37
2016-09-30 -35.08 11.12 5.87
2016-06-30 -37.15 11.40 6.70
2016-03-31 -31.18 11.01 7.42
2015-12-31 -35.38 12.74 8.42
2015-09-30 -31.98 10.03 7.50
2015-06-30 -33.44 9.93 7.99
2015-03-31 -37.21 10.61 8.58
2014-12-31 -38.00 10.15 9.39
2014-09-30 0.00 -38.52 10.16 8.75
2014-06-30 0.01 -41.79 9.64 8.50
2014-03-31 0.03 -43.78 8.76 9.15
2013-12-31 0.04 -41.95 8.31 8.26
2013-09-30 0.06 -43.41 7.73 9.34
2013-06-30 0.12 -40.68 7.20 9.06
2013-03-31 3.10 -30.95 6.14 7.68
2012-12-31 6.10 -23.51 5.06 7.74
2012-09-30 11.95 -10.15 4.00 4.72
2012-06-30 17.68 -2.52 3.48 -1.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Humanigen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Humanigen has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Humanigen improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Humanigen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Humanigen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Humanigen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Humanigen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Humanigen's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Humanigen's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Humanigen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Humanigen has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Humanigen Company Filings, last reported 2 months ago.

OTCPK:HGEN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 -9.55 3.80 0.18
2018-12-31 -8.11 3.50 0.81
2018-09-30 -6.69 3.19 2.04
2018-06-30 -7.07 1.81 0.27
2018-03-31 -5.41 1.38 1.56
2017-12-31 -24.34 19.37 0.74
2017-09-30 -21.58 16.98 1.10
2017-06-30 -14.69 10.72 0.10
2017-03-31 -8.87 10.04 4.04
2016-12-31 -4.38 4.29 2.91
2016-09-30 -0.19 1.24 2.91
2016-06-30 4.00 1.22 11.94
2016-03-31 0.31 0.00 6.58
2015-12-31 5.73 1.20 8.43
2015-09-30 4.14 7.17 7.65
2015-06-30 10.45 8.65 23.03
2015-03-31 16.11 9.77 30.22
2014-12-31 24.61 10.93 40.71
2014-09-30 33.79 12.18 49.11
2014-06-30 41.39 13.42 58.03
2014-03-31 50.67 9.19 62.70
2013-12-31 60.54 9.97 76.73
2013-09-30 38.31 9.93 54.94
2013-06-30 49.11 9.90 63.65
2013-03-31 60.33 9.86 76.85
2012-12-31 7.24 9.83 20.30
2012-09-30 19.13 4.82 24.74
2012-06-30 26.87 0.00 27.51
  • Humanigen has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Humanigen's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Humanigen has less than a year of cash runway based on current free cash flow.
  • Humanigen has less than a year of cash runway if free cash flow continues to reduce at historical rates of -45.5% each year.
X
Financial health checks
We assess Humanigen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Humanigen has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Humanigen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Humanigen dividends.
If you bought $2,000 of Humanigen shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Humanigen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Humanigen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:HGEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Humanigen has not reported any payouts.
  • Unable to verify if Humanigen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Humanigen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Humanigen has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Humanigen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Humanigen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Humanigen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Humanigen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Cameron Durrant
COMPENSATION $4,283,399
AGE 58
TENURE AS CEO 3.3 years
CEO Bio

Dr. Cameron Durrant, MD, MBA, is the Chairman and Chief Executive Officer of Humanigen, since January 2016. He was a Director and Lead Director of Immune Pharmaceuticals Inc respectively from July 2014 to September 10, 2018 and January 10, 2015 to September 10, 2018. He was elevated to that position after serving on the board of directors starting January 7, 2016. Dr. Durrant’s expertise and business career has revolved around transformations, whether for brands, business units, or small companies. He has particular therapeutic experience in infectious diseases, pediatrics and oncology – coupled with experience as a practicing physician. He has served as board chairman, lead independent director and as CEO for several specialty pharma or biotech companies in both the private and public sector. He has been involved in several exits and has raised significant funding from a variety of sources. He is currently a founding director of a private nanotech oncology company, Bexion Pharmaceuticals and on the board of two private medical device companies. Dr. Durrant is also founder of the start-up Taran Pharma Limited, a private, semi-virtual specialty pharma company developing and registering treatments in Europe for orphan conditions. Previously, Dr. Durrant was president and CEO of ECR Pharmaceuticals from September 2012 to April 2014 and a corporate officer of Hi-Tech Pharmacal; and the founder, Chairman, CEO and CFO of PediatRx, Inc., which marketed therapies for pediatric care, orphan conditions and oncology supportive care. His career has been built on extensive experience – including commercial, P&L, US and global responsibilities – as an operating executive at blue-chip pharmaceutical companies. Dr. Durrant has been President and CEO of PediaMed Pharmaceuticals, a company focused on bring important medicines to children in the US; and held senior executive positions at Johnson & Johnson and Pharmacia. He has served as Executive Chairman and CEO of Anavex (a public company), former CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation) and former board member of Topaz Pharmaceuticals (acquired by sanofi-aventis). He also had earlier roles at GlaxoSmithKline and Merck. He is a prior regional winner of the Ernst and Young ‘Entrepreneur of the Year’ award and a national finalist, named as a PharmaVoice Red Jacket honoree in 2017. Dr. Durrant earned his MD from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK and his MRCGP from the Royal College of General Practitioners, London, UK. He practiced medicine for eight years in the UK and Australia. He also earned his MBA from Henley Management College, Oxford, UK.

CEO Compensation
  • Cameron's compensation has increased whilst company is loss making.
  • Cameron's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Humanigen management team in years:

1.8
Average Tenure
  • The average tenure for the Humanigen management team is less than 2 years, this suggests a new team.
Management Team

Cameron Durrant

TITLE
Chairman & CEO
COMPENSATION
$4M
AGE
58
TENURE
3.3 yrs

Greg Jester

TITLE
Chief Financial Officer
COMPENSATION
$919K
AGE
50
TENURE
1.8 yrs

Tarek Sahmoud

TITLE
Chief Medical Officer
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Humanigen board of directors in years:

3
Average Tenure
58
Average Age
  • The tenure for the Humanigen board of directors is about average.
Board of Directors

Cameron Durrant

TITLE
Chairman & CEO
COMPENSATION
$4M
AGE
58
TENURE
3.4 yrs

Ronald Barliant

TITLE
Independent Director
COMPENSATION
$465K
AGE
73
TENURE
3.4 yrs

Timothy Morris

TITLE
Director
COMPENSATION
$444K
AGE
56
TENURE
3 yrs

Bob Savage

TITLE
Director
COMPENSATION
$388K
AGE
64
TENURE
1.3 yrs

Rainer Boehm

TITLE
Director
COMPENSATION
$384K
AGE
58
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Humanigen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Humanigen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company’s lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. The company has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase I/II study of lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

Details
Name: Humanigen, Inc.
HGEN
Exchange: OTCPK
Founded: 2000
$125,989,226
110,323,316
Website: http://www.humanigen.com
Address: Humanigen, Inc.
533 Airport Boulevard,
Suite 400,
Burlingame,
California, 94005,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK HGEN Common Stock Pink Sheets LLC US USD 31. Jan 2013
Number of employees
Current staff
Staff numbers
3
Humanigen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 00:38
End of day share price update: 2019/06/14 00:00
Last earnings filing: 2019/05/03
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.